Literature DB >> 26408659

Infection Exposure is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a Result of Pax5-Inherited Susceptibility.

Alberto Martín-Lorenzo1, Julia Hauer2, Carolina Vicente-Dueñas1, Franziska Auer2, Inés González-Herrero1, Idoia García-Ramírez1, Sebastian Ginzel3, Ralf Thiele4, Stefan N Constantinescu5, Christoph Bartenhagen6, Martin Dugas6, Michael Gombert2, Daniel Schäfer2, Oscar Blanco7, Andrea Mayado8, Alberto Orfao8, Diego Alonso-López9, Javier De Las Rivas10, César Cobaleda11, Maria Begoña García-Cenador12, Francisco Javier García-Criado12, Isidro Sánchez-García13, Arndt Borkhardt14.   

Abstract

UNLABELLED: Earlier in the past century, infections were regarded as the most likely cause of childhood B-cell precursor acute lymphoblastic leukemia (pB-ALL). However, there is a lack of relevant biologic evidence supporting this hypothesis. We present in vivo genetic evidence mechanistically connecting inherited susceptibility to pB-ALL and postnatal infections by showing that pB-ALL was initiated in Pax5 heterozygous mice only when they were exposed to common pathogens. Strikingly, these murine pB-ALLs closely resemble the human disease. Tumor exome sequencing revealed activating somatic, nonsynonymous mutations of Jak3 as a second hit. Transplantation experiments and deep sequencing suggest that inactivating mutations in Pax5 promote leukemogenesis by creating an aberrant progenitor compartment that is susceptible to malignant transformation through accumulation of secondary Jak3 mutations. Thus, treatment of Pax5(+/-) leukemic cells with specific JAK1/3 inhibitors resulted in increased apoptosis. These results uncover the causal role of infection in pB-ALL development. SIGNIFICANCE: These results demonstrate that delayed infection exposure is a causal factor in pB-ALL. Therefore, these findings have critical implications for the understanding of the pathogenesis of leukemia and for the development of novel therapies for this disease. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26408659     DOI: 10.1158/2159-8290.CD-15-0892

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  50 in total

Review 1.  Genetic defects in hematopoietic transcription factors and predisposition to acute lymphoblastic leukemia.

Authors:  Yoshihiro Gocho; Jun J Yang
Journal:  Blood       Date:  2019-07-16       Impact factor: 22.113

2.  Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing.

Authors:  Christoph Bartenhagen; Ute Fischer; Klaus Korn; Stefan M Pfister; Michael Gombert; Cai Chen; Vera Okpanyi; Julia Hauer; Anna Rinaldi; Jean-Pierre Bourquin; Cornelia Eckert; Jianda Hu; Armin Ensser; Martin Dugas; Arndt Borkhardt
Journal:  Haematologica       Date:  2017-02-02       Impact factor: 9.941

3.  A germ-line deletion of APOBEC3B does not contribute to subtype-specific childhood acute lymphoblastic leukemia etiology.

Authors:  Amelia D Wallace; Stephen S Francis; Xiaorong Shao; Adam J de Smith; Kyle M Walsh; Roberta Mckean-Cowdin; Xiaomei Ma; Gary Dahl; Lisa F Barcellos; Joseph L Wiemels; Catherine Metayer
Journal:  Haematologica       Date:  2017-10-12       Impact factor: 9.941

4.  Loss of Pax5 Exploits Sca1-BCR-ABLp190 Susceptibility to Confer the Metabolic Shift Essential for pB-ALL.

Authors:  Alberto Martín-Lorenzo; Franziska Auer; Lai N Chan; Idoia García-Ramírez; Inés González-Herrero; Guillermo Rodríguez-Hernández; Christoph Bartenhagen; Martin Dugas; Michael Gombert; Sebastian Ginzel; Oscar Blanco; Alberto Orfao; Diego Alonso-López; Javier De Las Rivas; Maria B García-Cenador; Francisco J García-Criado; Markus Müschen; Isidro Sánchez-García; Arndt Borkhardt; Carolina Vicente-Dueñas; Julia Hauer
Journal:  Cancer Res       Date:  2018-02-28       Impact factor: 12.701

Review 5.  A causal mechanism for childhood acute lymphoblastic leukaemia.

Authors:  Mel Greaves
Journal:  Nat Rev Cancer       Date:  2018-08       Impact factor: 60.716

6.  IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity.

Authors:  Dennis Das Gupta; Christoph Paul; Nadine Samel; Maria Bieringer; Daniel Staudenraus; Federico Marini; Hartmann Raifer; Lisa Menke; Lea Hansal; Bärbel Camara; Edith Roth; Patrick Daum; Michael Wanzel; Marco Mernberger; Andrea Nist; Uta-Maria Bauer; Frederik Helmprobst; Malte Buchholz; Katrin Roth; Lorenz Bastian; Alina M Hartmann; Claudia Baldus; Koichi Ikuta; Andreas Neubauer; Andreas Burchert; Hans-Martin Jäck; Matthias Klein; Tobias Bopp; Thorsten Stiewe; Axel Pagenstecher; Michael Lohoff
Journal:  Cell Death Differ       Date:  2022-04-22       Impact factor: 15.828

7.  An intact gut microbiome protects genetically predisposed mice against leukemia.

Authors:  Carolina Vicente-Dueñas; Stefan Janssen; Marina Oldenburg; Franziska Auer; Inés González-Herrero; Ana Casado-García; Marta Isidro-Hernández; Javier Raboso-Gallego; Philipp Westhoff; Aleksandra A Pandyra; Daniel Hein; Katharina L Gössling; Diego Alonso-López; Javier De Las Rivas; Sanil Bhatia; Francisco Javier García-Criado; María Begoña García-Cenador; Andreas P M Weber; Karl Köhrer; Julia Hauer; Ute Fischer; Isidro Sánchez-García; Arndt Borkhardt
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

8.  Infection and the Perils of B-cell Activation.

Authors:  Mel Greaves; Markus Müschen
Journal:  Cancer Discov       Date:  2015-12       Impact factor: 39.397

Review 9.  Infectious triggers and novel therapeutic opportunities in childhood B cell leukaemia.

Authors:  Cesar Cobaleda; Carolina Vicente-Dueñas; Isidro Sanchez-Garcia
Journal:  Nat Rev Immunol       Date:  2021-02-08       Impact factor: 53.106

Review 10.  Cell Fate Decisions: The Role of Transcription Factors in Early B-cell Development and Leukemia.

Authors:  Ute Fischer; Jun J Yang; Tomokatsu Ikawa; Daniel Hein; Carolina Vicente-Dueñas; Arndt Borkhardt; Isidro Sánchez-García
Journal:  Blood Cancer Discov       Date:  2020-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.